Skip to main content
SpringerLink
Log in

Medication Management of Fragile X Syndrome

  • Reference work entry
Comprehensive Guide to Autism

Abstract

This section will review developments in the medication management of fragile X syndrome. This includes medication use targeting associated symptoms of fragile X syndrome such as aggression, self-injury, and hyperactivity and other more core symptoms like anxiety, social withdrawal, and cognitive disability. Given the overlap between fragile X syndrome and autism spectrum disorders, there is hope that drugs that show promise as targeted treatments in fragile X syndrome may also benefit persons with autism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 1,199.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aman MG, Singh NN, et al. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;5:485–91.

    Google Scholar 

  • Amaria R, Billeisen L, et al. Medication use in fragile X syndrome. Mental Health Asp Dev Disabil. 2001;4:89–93.

    Google Scholar 

  • Bailey Jr DB, Raspa M, et al. Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey. J Dev Behav Pediatr. 2012;33(1):62–9.

    Article  PubMed  Google Scholar 

  • Bear MF, Huber KM, et al. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370–7.

    Article  PubMed  Google Scholar 

  • Bear MF. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav. 2005;4(6):393–8.

    Article  PubMed  Google Scholar 

  • Berry-Kravis E, Hessl D, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009;46(4):266–71.

    Article  PubMed  Google Scholar 

  • Berry-Kravis EM, Hessl D, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012;4(152):152ra127.

    Article  PubMed  Google Scholar 

  • Berry-Kravis E, Krause SE, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol. 2006;16(5):525–40.

    Article  PubMed  Google Scholar 

  • Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome – present and future. Ment Retard Dev Disabil Res Rev. 2004;10(1):42–8.

    Article  PubMed  Google Scholar 

  • Cheah BC, Vucic S, et al. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17(18):1942–199.

    Article  PubMed  Google Scholar 

  • Clifford S, Dissanayake C, et al. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord. 2007;37(4):738–47.

    Article  PubMed  Google Scholar 

  • D’Hulst C, De Geest N, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 2006;1121(1):238–45.

    Article  PubMed  Google Scholar 

  • D’Hulst C, Kooy RF. The GABAA receptor: a novel target for treatment of fragile X? Trends Neurosci. 2007;30(8):425–31.

    Article  PubMed  Google Scholar 

  • de Vries BB, Mohkamsing S, et al. Screening with the FMR1 protein test among mentally retarded males. Hum Genet. 1998;103(4):520–2.

    Article  PubMed  Google Scholar 

  • Dolen G, Bear MF. Courting a cure for fragile X. Neuron. 2005;45(5):642–4.

    Article  PubMed  Google Scholar 

  • Dolen G, Bear MF. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol. 2008;586(6):1503–8.

    Article  PubMed  Google Scholar 

  • Dolen G, Osterweil E, et al. Correction of fragile X syndrome in mice. Neuron. 2007;56(6):955–62.

    Article  PubMed  Google Scholar 

  • Erickson CA, Mullett JE, et al. Open-label memantine in fragile X syndrome. J Autism Dev Disord 2009;39(12):1629–1635.

    Article  PubMed  Google Scholar 

  • Erickson CA. Prospective open-label trial of acamprosate in youth with fragile X syndrome: a pilot study including biomarker assay. International fragile X syndrome meeting; 2012; Miami.

    Google Scholar 

  • Erickson CA, Stigler KA, et al. Managing maladaptive behaviors in fragile X patients. Curr Psychiatry. 2006;5(10):80–92.

    Google Scholar 

  • Erickson CA, Mullett JE, et al. Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord. 2010;40(11):1412–6.

    Article  PubMed  Google Scholar 

  • Erickson CA, Stigler KA, et al. A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology (Berl). 2011a;216(1):85–90.

    Article  Google Scholar 

  • Erickson CA, Weng N, et al. Open-label riluzole in fragile X syndrome. Brain Res. 2011b;1380:264–70.

    Article  PubMed  Google Scholar 

  • Florencia G, Irene S, et al. Fragile-X mental retardation: molecular diagnosis in argentine patients. J Biochem Mol Biol. 2006;39(6):766–73.

    Article  PubMed  Google Scholar 

  • Gerard B, Le Heuzey MF, et al. Systematic screening for fragile X syndrome in a cohort of 574 mentally retarded children. Ann Genet. 1997;40(3):139–44.

    PubMed  Google Scholar 

  • Guy W. ECDEU assessment manual for psychopharmacology, publication No. 76–338. Washington, DC: DHEW, NIMH; 1976.

    Google Scholar 

  • Hagerman RJ, Fulton MJ, et al. A survey of fluoxetine therapy in fragile X syndrome. Dev Brain Dysfunct. 1994;7:155–64.

    Google Scholar 

  • Hagerman RJ, Murphy MA, et al. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet. 1988;30(1–2):377–92.

    Article  PubMed  Google Scholar 

  • Hagerman RJ, Riddle JE, et al. Survey of the efficacy of clonidine in fragile X syndrome. Dev Brain Dysfunct. 1995;8(4–6):336–44.

    Google Scholar 

  • Henderson C, Wijetunge L, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012;4(152):152ra128.

    Article  PubMed  Google Scholar 

  • Jacquemont S, Curie A, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3(64):64ra61.

    Article  Google Scholar 

  • Kiefer F, Mann K. Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy. Curr Pharm Des. 2010;16(19):2098–102.

    Article  PubMed  Google Scholar 

  • Kim SH, Markham JA, et al. Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome. Proc Natl Acad Sci USA. 2008;105(11):4429–34.

    Article  PubMed  Google Scholar 

  • Kronk R, Bishop EE, et al. Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey. Sleep. 2010;33(5):679–87.

    PubMed  Google Scholar 

  • Lindemann L, Jaeschke G, et al. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J Pharmacol Exp Ther. 2011;339(2):474–86.

    Article  PubMed  Google Scholar 

  • Nakamoto M, Nalavadi V, et al. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci USA. 2007;104(39):15537–42.

    Article  PubMed  Google Scholar 

  • Posey DJ, Aman MG, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry. 2007;61(4):538–44.

    Article  PubMed  Google Scholar 

  • Sansone SM, Widaman KF, et al. Psychometric study of the aberrant behavior checklist in fragile x syndrome and implications for targeted treatment. J Autism Dev Disord. 2012;42(7):1377–92.

    Article  PubMed  Google Scholar 

  • Simonoff E, Bolton P, et al. Mental retardation: genetic findings, clinical implications and research agenda. J Child Psychol Psychiatry. 1996;37(3):259–80.

    Article  PubMed  Google Scholar 

  • Stigler KA, Desmond LA, et al. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14(1):49–56.

    Article  PubMed  Google Scholar 

  • Symons FJ, Clark RD, et al. Self-injurious behavior in young boys with fragile X syndrome. Am J Med Genet A. 2003;118A(2):115–21.

    Article  PubMed  Google Scholar 

  • Torrioli MG, Vernacotola S, et al. Double-blind, placebo-controlled study of l-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet. 1999;87(4):366–8.

    Article  PubMed  Google Scholar 

  • Torrioli MG, Vernacotola S, et al. A double-blind, parallel, multicenter comparison of l-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A. 2008;146(7):803–12.

    Article  PubMed  Google Scholar 

  • Torrioli M, Vernacotola S, et al. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A. 2010;152A(6):1420–7.

    PubMed  Google Scholar 

  • von Gontard A, Backes M, et al. Psychopathology and familial stress – comparison of boys with fragile X syndrome and spinal muscular atrophy. J Child Psychol Psychiatry. 2002;43(7):949–57.

    Article  Google Scholar 

  • Wei H, Dobkin C, et al. The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. PLoS One. 2012;7(5):e36981.

    Article  PubMed  Google Scholar 

  • Weng N, Weiler IJ, et al. Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(7):1253–7.

    Article  PubMed  Google Scholar 

  • Wirojanan J, Jacquemont S, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5(2):145–50.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, Department of Psychiatry, Indiana University, 702 Barnhill Drive, ROC 4300, 46202-5200, Indianapolis, IN, USA

    Rebecca C. Shaffer

  2. Division of Child and Adolescent Psychiatry, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, MLC 4002, 45229, Cincinnati, OH, USA

    Craig A. Erickson, Logan K. Wink & Tori L. Schaefer

Authors
  1. Craig A. Erickson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Logan K. Wink
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tori L. Schaefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rebecca C. Shaffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Craig A. Erickson .

Editor information

Editors and Affiliations

  1. Department of Biomedical Sciences, University of Westminster, Faculty of Science & Technology, London, United Kingdom

    Vinood B. Patel

  2. Nutritional Sciences Division and Genomics Centre, King's College London, London, United Kingdom

    Victor R. Preedy

  3. Faculty of Society and Health, Buckinghamshire New University, Middlesex, United Kingdom

    Colin R. Martin

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this entry

Cite this entry

Erickson, C.A., Wink, L.K., Schaefer, T.L., Shaffer, R.C. (2014). Medication Management of Fragile X Syndrome. In: Patel, V., Preedy, V., Martin, C. (eds) Comprehensive Guide to Autism. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4788-7_188

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-4788-7_188

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-4787-0

  • Online ISBN: 978-1-4614-4788-7

  • eBook Packages: Behavioral Science

Publish with us

Policies and ethics

Search

Navigation